The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience
The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience
复制标题
DOI：
10.21873/anticanres.15791
复制
发表时间：
2022-05
影响因子：
2
通讯作者：
M. Hidaka;T. Hara;A. Soyama;R. Sasaki;H. Matsushima;Takayuki Tanaka;T. Hamada;H. Imamura;T. Adachi;K. Kanetaka;H. Miyaaki;Shinji Okano;S. Eguchi
中科院分区：
文献类型：
--
作者：
M. Hidaka;T. Hara;A. Soyama;R. Sasaki;H. Matsushima;Takayuki Tanaka;T. Hamada;H. Imamura;T. Adachi;K. Kanetaka;H. Miyaaki;Shinji Okano;S. Eguchi
背景：近年来，分子靶向药物（mta）的疗效已得到证实。然而，包括肝切除在内的多学科治疗的结果仍不清楚。本研究评估了MTA治疗晚期不可切除的肝细胞癌（HCC）的结果，目的是实现肝切除术。患者和方法：本研究包括9例接受Lenvatinib以实现不可切除HCC转化手术的患者。患者特点：中位肿瘤大小10 cm， 5例侵犯血管，2例多发肿瘤，中位治疗时间8周，4例因不良反应减少剂量，1例因肿瘤生长停止治疗。结果：经修订的实体瘤疗效评价标准（mRECIST）评价，3例患者部分缓解，5例患者持续，1例患者进展，肝切除率为88%。4例患者（50%）术后复发，中位无复发生存期为12.7个月；然而，治疗复发是成功的，所有患者都活着。结论：Lenvatinib可通过肿瘤缩小患者在适当的时间进行根治性切除，改善血管侵犯及多发病变的HCC预后。
Background: The efficacy of molecular-targeted agents (MTAs) has been demonstrated in recent years. However, the results of multidisciplinary treatment including hepatic resection are still unclear. The present study evaluated the outcomes of MTA treatment for advanced, unresectable hepatocellular carcinoma (HCC), with the goal of achieving liver resection, in our department. Patients and Methods: Nine patients in whom Lenvatinib had been administered to achieve conversion surgery for unresectable HCC were included in this study. The patient characteristics were as following: median tumor size of 10 cm, vascular invasion in 5 cases, multiple tumors in 2 cases, median treatment duration of 8 weeks, dose reduction due to side effects in 4 patients, and discontinuation of treatment in 1 patient due to tumor growth. Results: The efficacy by modified Response Evaluation Criteria in Solid Tumors (mRECIST) was partial response in 3, sustained disease in 5 and progressive disease in 1, while the liver resection rate was 88%. Four patients (50%) had recurrence after resection, and the median recurrence-free survival was 12.7 months; however, treatment for recurrence was successful and all patients are alive. Conclusion: Lenvatinib may improve the prognosis of HCC with vascular invasion and multiple lesions by achieving radical resection at the appropriate time for patients with tumor shrinkage.